Bristol-Myers Squibb Co., of New York, received the requisite number of consents to adopt the proposed amendments with respect to all outstanding notes of Celgene Corp., of Summit, N.J. The settlement of the early tenders will occur on or about the closing date of Bristol-Myers Squibb's acquisition of Celgene. (See BioWorld, Jan. 8, 2019.)